TARRYTOWN, N.Y.--(BUSINESS WIRE)--Aug. 3, 2006--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the second quarter of 2006. The Company reported a net loss of $23.6 million, or $0.41 per share (basic and diluted), for the second quarter of 2006 compared with a net loss of $27.0 million, or $0.48 per share (basic and diluted), for the second quarter of 2005. The Company reported a net loss of $44.0 million, or $0.77 per share (basic and diluted), for the six months ended June 30, 2006 compared with a net loss of $31.1 million, or $0.56 per share (basic and diluted), for the same period in 2005. Results for the first six months of 2005 included other contract income of $30.6 million resulting from one-time, non-recurring payments of $25.0 million from the sanofi-aventis Group and $5.6 million from The Procter & Gamble Company in connection with amendments to the Company’s collaboration agreements with sanofi-aventis and Procter & Gamble.
